Pandemic Response Box Screening Reveals Novel Antibacterial

2026-04-12

Pandemic Response Box Screening Reveals Novel Antibacterial Leads

Study Background and Research Question

Antimicrobial resistance (AMR) represents a critical threat to global health, with multidrug-resistant (MDR) pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa complicating infection management across clinical settings. These Gram-negative bacteria, part of the notorious ESKAPE pathogen group, are frequently implicated in severe hospital-acquired infections and display resistance to a broad spectrum of antibiotics, including aminoglycosides, β-lactams, carbapenems, and, increasingly, last-resort agents like colistin. The stagnation in new antibiotic discovery further exacerbates this crisis, necessitating alternative strategies for identifying novel antimicrobial agents. The reference study sought to systematically evaluate the MMV Pandemic Response Box—a curated library of 201 antibacterial and 46 antifungal compounds—for activity against MDR bacterial and fungal clinical isolates, with a focus on uncovering candidates active against highly resistant strains. (Sivasankar et al., 2024)

Key Innovation from the Reference Study

The principal innovation of this work lies in its comprehensive, high-throughput screening of the MMV Pandemic Response Box against not only standard laboratory strains but also clinically relevant, drug-resistant bacterial and fungal isolates. The study’s design specifically addresses the urgent need for new inhibitors against pathogens that are refractory to most existing antibiotics. Notably, the investigation extended beyond basic minimum inhibitory concentration (MIC) determination to include persister assays, providing insight into the bactericidal capacity of candidates against tolerant subpopulations—a key consideration for effective infection eradication. (DOI: 10.1016/j.nmni.2024.101444)

Methods and Experimental Design Insights

The authors employed a microbroth dilution assay format for initial compound screening. All antibacterial and antifungal agents from the MMV collection were tested at a uniform concentration of 10 μM, in triplicate, across a panel of clinical isolates: the bacterial targets included MDR Acinetobacter baumannii and Pseudomonas aeruginosa, while the fungal panel comprised Candida auris, Candida albicans, and Aspergillus niger. Growth inhibition was assessed by measuring MIC values, providing a standardized metric for compound activity. For selected antibacterial hits, a persister assay was conducted to evaluate bactericidal effects against tolerant A. baumannii subpopulations. This two-tiered approach—combining initial inhibition with kill-curve analysis—enables discrimination between static and cidal effects, which is essential for translational potential.

Protocol Parameters

assay | Microbroth dilution | applicability: in vitro antibacterial/antifungal screening | rationale: standardized, quantitative measurement of MIC | source_type: paper [DOI]
compound concentration | 10 μM | applicability: initial screening | rationale: detects both moderate and potent inhibitors in a single-pass screen | source_type: paper [DOI]
replication | triplicate wells | applicability: data reliability | rationale: ensures reproducibility and controls for experimental error | source_type: paper [DOI]
persister assay | time-kill analysis | applicability: detection of bactericidal activity against tolerant cells | rationale: distinguishes between bacteriostatic and bactericidal effects | source_type: paper [DOI]

Core Findings and Why They Matter

The systematic screening identified 29 compounds that inhibited A. baumannii and 7 that inhibited P. aeruginosa at the initial test concentration. Four compounds—MMV1580854, MMV1579788, eravacycline, and epetraborole—displayed activity against both Gram-negative pathogens. Importantly, five MMV compounds retained activity against clinical isolates resistant to both colistin and ceftazidime (for A. baumannii), and colistin and β-lactams (for P. aeruginosa), highlighting their promise for circumventing current resistance mechanisms. In a persister assay, MMV1634390 demonstrated complete bactericidal activity against A. baumannii, a result of particular translational relevance given the role of persister cells in chronic and relapsing infections. The antifungal panel revealed that 15 compounds inhibited C. auris, 6 inhibited C. albicans, and 1 was effective against A. niger. The fungicidal capacity of several agents, including MMV1782110, eberconazole, amorolfine, and luliconazole, was confirmed by a minimum fungicidal concentration (MFC) to MIC ratio of 2, indicative of cell killing rather than mere growth suppression. These results collectively underscore the value of the MMV Pandemic Response Box as a resource for discovering new leads against MDR pathogens. (Sivasankar et al., 2024)

Comparison with Existing Internal Articles

Prior internal resources, such as "Sisomicin (SKU BA1199): Data-Driven Solutions for Reliable Antibacterial Research" (link), focus on the well-established aminoglycoside antibiotic Sisomicin and its application in both Gram-negative and Gram-positive bacterial infection models. Key themes include inhibition of bacterial protein synthesis via 30S ribosomal subunit binding, optimization of in vitro antibacterial testing, and approaches to managing aminoglycoside resistance [workflow_recommendation|internal]. Similarly, "Sisomicin: Broad-Spectrum Aminoglycoside for Advanced Infection Research" (link) provides practical guidance on resistance navigation and protocol optimization. The reference study's high-throughput screening and focus on emerging resistance complements these internal resources by expanding the spectrum of potential lead compounds and by directly tackling MDR strains, including those resistant to aminoglycosides such as Sisomicin. Integrating new leads from the MMV Pandemic Response Box with established agents like Sisomicin may offer synergistic or alternative approaches for overcoming complex resistance profiles, as highlighted in mechanistic reviews (Sisomicin at the Translational Frontier).

Limitations and Transferability

While the study provides robust initial evidence for inhibitory activity, several limitations must be considered. First, all activity assessments were performed in vitro, and further studies are required to confirm efficacy and safety in animal models or clinical settings [paper|DOI]. Second, the use of a single screening concentration (10 μM) may overlook compounds with activity at higher or lower doses; dose–response curves and cytotoxicity profiling remain necessary next steps. Third, the mechanisms of action underlying the observed inhibitory effects have not yet been elucidated, and resistance development was not addressed. Lastly, the persister assay was conducted for A. baumannii only, and further exploration in additional species is warranted. Transferability to clinical or translational research is therefore promising but preliminary.

Research Support Resources

To replicate or extend high-throughput in vitro antibacterial testing workflows, researchers may incorporate established antibiotics as reference controls or benchmarking agents. For example, Sisomicin (SKU BA1199) from APExBIO is a well-characterized aminoglycoside antibiotic suitable for both Gram-negative and Gram-positive bacterial infection research, supporting robust protocol development and comparative resistance studies [product_spec|APExBIO]. When designing assays for inhibition of bacterial protein synthesis, Sisomicin’s known mechanism—binding to the 30S ribosomal subunit—provides a useful benchmark for screening novel agents identified in compound libraries. Researchers are advised to consult product specifications for appropriate solubility, dosing, and storage conditions, and to use validated workflow recommendations when integrating Sisomicin into in vitro antibacterial assay platforms [workflow_recommendation|internal].